GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
151.01
-1.52 (-1.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close152.53
Open154.76
Bid150.50 x 800
Ask157.00 x 800
Day's Range150.74 - 155.60
52 Week Range95.65 - 164.76
Volume292,001
Avg. Volume408,329
Market Cap4.259B
Beta2.67
PE Ratio (TTM)N/A
EPS (TTM)-9.68
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est179.20
Trade prices are not sourced from all markets
  • Reuters17 hours ago

    Key marijuana drug approval looms as cannabis goes mainstream

    Evidence that cannabis can ease epilepsy and other conditions is building as a British company counts down to what would be the first U.S. government approval for a prescription drug derived from the marijuana plant. GW Pharmaceuticals (GWPH.O), which has spent 20 years developing medicines from cannabis, is hoping for a Food and Drug Administration (FDA) green light by June 27, after winning support from an advisory panel in April. Some parents already use cannabis to help children with severe forms of epilepsy, but such therapy is not monitored or licensed.

  • Reuters18 hours ago

    Key marijuana drug approval looms as cannabis goes mainstream

    Evidence that cannabis can ease epilepsy and other conditions is building as a British company counts down to what would be the first U.S. government approval for a prescription drug derived from the marijuana plant. GW Pharmaceuticals, which has spent 20 years developing medicines from cannabis, is hoping for a Food and Drug Administration (FDA) green light by June 27, after winning support from an advisory panel in April. "We've learnt a huge amount about cannabis," said Valerie Curran, head of the clinical psychopharmacology unit at University College London.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Stocks to Watch: Canopy Growth and GW Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / As Canada officially legalized recreational marijuana this week, shares of Canopy Growth skyrocketed after announcing a multi-year agreement with Neptune Technologies & Bioressources Inc. Shares of GW Pharmaceuticals were modestly in the red despite any news. Canopy Growth Corporation shares closed up almost 4% on Tuesday with nearly 4.5 million shares traded. The stock hit a brand new high of $32.88 yesterday after it was revealed that Neptune Technologies & Bioressources Inc. has entered into a multi-year agreement with Canopy Growth to supplement Canopy Growth's extraction, refinement, and extract product formulation capacity.

  • Some fear changes to state laws as US weighs pot medicine
    Associated Press3 days ago

    Some fear changes to state laws as US weighs pot medicine

    COLORADO SPRINGS, Colo. (AP) — Some American parents who for years have used cannabis to treat severe forms of epilepsy in their children are feeling more cautious than celebratory as U.S. regulators near a decision on whether to approve the first drug derived from the marijuana plant.

  • Investopedia3 days ago

    Waiting to Exhale: The Case for Cannabis Investing

    The former, a large swath of the global population, is tainted by 90 years of misinformation that’s been perpetuated by those benefiting from the status quo, which began with William Randolph Hearst defending his paper empire and continues with big pharma protecting their prescriptions.They view cannabis as a gateway drug or cite moral conflicts and the conversation ends there.  We believe many of them will evolve into late-cycle adopters that provide future layers of demand.

  • InvestorPlace4 days ago

    GW Pharmaceuticals’ New Drug Is a Step Toward Marijuana Legalization

    The news that GW Pharmaceuticals PLC (ADR) (NASDAQ:GWPH) will soon see Epidiolex, the company’s experimental drug that treats epilepsy, is fantastic in and of itself. Here’s why Epidiolex’s approval should matter to everyone participating in the burgeoning cannabis industry and not just GWPH shareholders. The biggest problem facing the cannabis industry at the moment as it pertains to Cannabidiol (CBD), the main ingredient of Epidiolex, is that hemp-derived CBD is technically considered legal throughout the U.S. as a result of the Agricultural Act of 2014 and exempted from Drug Enforcement Administration (DEA) regulation under a 2006 law, while marijuana-derived CBD is only legal in 30 states and Washington, D.C.

  • 7 Reasons Marijuana Won't Be Legalized in the U.S.
    Motley Fool5 days ago

    7 Reasons Marijuana Won't Be Legalized in the U.S.

    Despite growing public support, cannabis is unlikely to get a green light from Congress anytime soon.

  • Why Marijuana Stock GW Pharmaceuticals Gained 21% in May
    Motley Fool8 days ago

    Why Marijuana Stock GW Pharmaceuticals Gained 21% in May

    The biotech has an FDA decision pending on its epilepsy drug.

  • Market Exclusive8 days ago

    Market Morning: Bitcoin Untethered, Fed Talks Marijuana, Whole Amazon Foods Clash

    Bitcoin Untethered, Literally Speculation is mounting that the price of bitcoin (BTC-USD) and other altcoins like ethereum (ETH-USD) and bitcoin cash (BCH-USD) has been manipulated using a scheme pretty much identical to what the Federal Reserve uses to inflate the price of US treasuries. Tether (USDT-USD), a crytpocurrency token supposedly backed by, or “tethered” to […] The post Market Morning: Bitcoin Untethered, Fed Talks Marijuana, Whole Amazon Foods Clash appeared first on Market Exclusive.

  • Forget Canada! This Marijuana Vote Is Far More Important
    Motley Fool12 days ago

    Forget Canada! This Marijuana Vote Is Far More Important

    This cannabis decision has a real shot to lead to reform in the U.S.

  • Better Marijuana Stock: GW Pharmaceuticals vs. Cara Therapeutics
    Motley Fool12 days ago

    Better Marijuana Stock: GW Pharmaceuticals vs. Cara Therapeutics

    Which stock wins in a one-on-one battle between two biotechs with cannabinoid pipeline candidates?

  • The Zacks Analyst Blog Highlights: Innovative Industrial Properties and GW Pharmaceuticals
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Innovative Industrial Properties and GW Pharmaceuticals

    The Zacks Analyst Blog Highlights: Innovative Industrial Properties and GW Pharmaceuticals

  • Canada to Legalize Marijuana: Will Cannabis Industry Bloom?
    Zacks15 days ago

    Canada to Legalize Marijuana: Will Cannabis Industry Bloom?

    The marijuana industry is blooming at present, following the legalization of both medical and now recreational cannabis in Canada.

  • GlobeNewswire16 days ago

    GW Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

    GW Pharmaceuticals plc (GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 10:00 a.m. PT at the Terranea Resort, in Rancho Palos Verde, CA. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.

  • GlobeNewswire16 days ago

    Recent Analysis Shows Clementia Pharmaceuticals, Superior Group of Companies, ACM Research, Atlantic Capital Bancshares, Customers, and GW Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia ...

  • Better Marijuana Stock: Scotts Miracle-Gro vs. GW Pharmaceuticals
    Motley Fool19 days ago

    Better Marijuana Stock: Scotts Miracle-Gro vs. GW Pharmaceuticals

    Which stock wins in a match-up between a big supplier to the marijuana industry and the world's top marijuana biotech?

  • Key FDA Events in June Investors Need to Watch Out For
    Zacks21 days ago

    Key FDA Events in June Investors Need to Watch Out For

    Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.

  • 3 Biotechs With Huge FDA Decisions in June
    Motley Fool22 days ago

    3 Biotechs With Huge FDA Decisions in June

    The clock is ticking for these biotechs hoping to score key regulatory victories.

  • Benzinga23 days ago

    Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on May 29) Ascendis Pharma A/S (NASDAQ: ASN ) ASLAN PHARMACEUTICALS ...

  • Investopedia24 days ago

    Most-Shorted Marijuana Stocks

    This year has been a mixed bag for marijuana stocks. After an initial rally at the start of this year, marijuana stocks have mostly been on a downward slide. The North American Marijuana Index, which is a basket of 41 tickers spanning the marijuana supply chain, is down by 19% since the start of this year, as of this writing.

  • Rescheduling Marijuana in the U.S. Could Backfire
    Motley Fool26 days ago

    Rescheduling Marijuana in the U.S. Could Backfire

    Despite cannabis being entirely illegal now, a move to Schedule II at the federal level could actually make things worse.

  • GW Pharmaceuticals plc’s (NASDAQ:GWPH) Earnings Dropped -141.94%, How Did It Fare Against The Industry?
    Simply Wall St.27 days ago

    GW Pharmaceuticals plc’s (NASDAQ:GWPH) Earnings Dropped -141.94%, How Did It Fare Against The Industry?

    Examining how GW Pharmaceuticals plc (NASDAQ:GWPH) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...

  • ACCESSWIRE29 days ago

    Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Taro Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / May 24, 2018 / U.S. markets rebounded modestly on Wednesday, following the release of Fed's minutes of the meeting, which suggest that the central bank will be slightly dovish ...

  • Benzingalast month

    Here's Why The Marijuana ETF Could Be A Short-Covering Idea

    “A key development for the US Marijuana industry came on April 13th, when President Trump confirmed he had promised Colorado Senator Cory Gardner that US AG Jeff Sessions revocation of the Cole memo will not affect the state's legal Marijuana industry,” said IHS Markit in a recent research note. “That was a very timely update, with the combined market cap for Marijuana related stocks hitting a 2018 low on April 9th. Home to over $380 million in assets under management, MJ tracks the Prime Alternative Harvest Index.

  • This Latest Marijuana Survey Should Be Great News for Cannabis-Focused Biotechs
    Motley Foollast month

    This Latest Marijuana Survey Should Be Great News for Cannabis-Focused Biotechs

    No pain, big gain? There could be an untapped market for cannabinoids that biotechs aren't aggressively pursuing yet.